ABSTRACT
Wu Shou was a doctor in a medical family in Qiantang, Zhejiang in the Ming Dynasty. He was promoted as a medical officer in the local government and the Imperial Academy of Medicine. His work, considered a masterpiece Shang Han Yun Yao Quan Shu was published around 1505. The series consisted of four volumes. The main content of the book focused on the taxonomy study to the Treatise on Febrile Diseases (Shang Han Lun). Wu Shou was politically accused of being a person who pursued fame and fortune but lacked medical skills because of the conflicts and contradiction between medical officials and the political service system in the period of the Chenghua and Hongzhi in the Ming Dynasty. However, his medical and academic thinking and skills for typhoid treatment shown in the book demonstrated that they were not as awful as what was described at that time.
Subject(s)
Medicine, Chinese Traditional , Physicians , Humans , Publications , Academies and Institutes , ChinaABSTRACT
Yi Wan She, as a medical association in the Huzhou area, was organised by Lu Mingquan, Lu Shilong, Jin Desheng and other doctors in the late Ming Dynasty, developing daily medical theoretical discussions. It built up a hospital named Tian, paid deference to ancient medical doctors, and participated in activities to fight epidemics, organised by Hui Min Pharmacy, such as drug delivery, as an association of local affairs. This was recorded in Yi Wan She Cao and Lu Shi San Shi Yi Yan.
Subject(s)
Physicians , China , HumansABSTRACT
The Yijing Dazhi (, Great Illustrated Directions on Medical Classics) was written by Haiyan He Yue in the Ming Dynasty. This book cited some sections from the Danxi Yi An ( , Danxi's Medical Cases), and some cases in this book were new discoveries. Using the method of philology, this paper compared the cited sections from the Danxi Yi An () in The Yijing Dazhi with the medical records in Danxi Yi An (), Gezhi Yu Lun (, Further Discourses on the Properties of Things), Danxi Zuanyao (, Collected Essentials of Master Danxi's Medical Book), and Danxi Zhifa Xinyao (, Heart and Essentials of Danxi's Treatment Methods). It found that Danxi Yi An() and Danxi Yi An () are actually two individual books. In addition, the contents of Yijing Dazhi cited from Danxi Yi An () are well preserved and have important reference value for collating the medical records of Zhu Danxi in other relevant medical archives.
Subject(s)
Books , Philology , China , Medicine, Chinese Traditional , WritingABSTRACT
Drug resistance in cells is a major impedance to successful treatment of lung cancer. Taxus chinensis var. inhibits the growth of tumor cells and promotes the synthesis of interleukins 1 and 2 and tumor necrosis factor, enhancing immune function. In this study, T. chinensis var.-induced cell death was analyzed in lung cancer cells (H460) enriched for stem cell growth in a defined serum-free medium. Taxus-treated stem cells were also analyzed for Rhodamine 123 (Rh-123) expression by flow cytometry, and used as a standard functional indicator of MDR. The molecular basis of T. chinensis var.-mediated drug resistance was established by real-time PCR analysis of ABCC1, ABCB1, and lung resistance-related protein (LRP) mRNA, and western blot analysis of MRP1, MDR1, and LRP. Our results revealed that stem cells treated with higher doses of T. chinensis var. showed significantly lower growth inhibition rates than did H460 cells (P < 0.05). The growth of stem and H460 cells treated with a combination of T. chinensis var. and cisplatin was also significantly inhibited (P < 0.05). Rh-123 was significantly accumulated in the intracellular region and showed delayed efflux in stem cells treated with T. chinensis var. (P < 0.05), compared to those treated with verapamil. T. chinensis var.-treated stem cells showed significant downregulation of the ABCC1, ABCB1, and LRP mRNA and MRP1, MDR1, and LRP (P < 0.05) compared to H460 cells. Thus, T. chinensis var.-mediated downregulation of MRP1, MDR1, and LRP might contribute to the reversal of drug resistance in non-small cell lung cancer stem cells.
Subject(s)
Antineoplastic Agents/pharmacology , Drug Resistance, Neoplasm/drug effects , Gene Expression Regulation, Neoplastic , Neoplastic Stem Cells/drug effects , Plant Extracts/pharmacology , Taxus/chemistry , ATP Binding Cassette Transporter, Subfamily B/antagonists & inhibitors , ATP Binding Cassette Transporter, Subfamily B/genetics , ATP Binding Cassette Transporter, Subfamily B/metabolism , Antineoplastic Agents/chemistry , Carcinoma, Non-Small-Cell Lung/drug therapy , Carcinoma, Non-Small-Cell Lung/genetics , Carcinoma, Non-Small-Cell Lung/metabolism , Carcinoma, Non-Small-Cell Lung/pathology , Cell Line, Tumor , Cisplatin/pharmacology , Drug Combinations , Drug Resistance, Neoplasm/genetics , Drugs, Chinese Herbal , Humans , Lung Neoplasms/drug therapy , Lung Neoplasms/genetics , Lung Neoplasms/metabolism , Lung Neoplasms/pathology , Multidrug Resistance-Associated Proteins/antagonists & inhibitors , Multidrug Resistance-Associated Proteins/genetics , Multidrug Resistance-Associated Proteins/metabolism , Neoplastic Stem Cells/metabolism , Neoplastic Stem Cells/pathology , Plant Extracts/chemistry , Rhodamine 123/metabolism , Signal Transduction , Vault Ribonucleoprotein Particles/antagonists & inhibitors , Vault Ribonucleoprotein Particles/genetics , Vault Ribonucleoprotein Particles/metabolismABSTRACT
Our 10-year translational study of the oral premalignant lesion (OPL) model has advanced the basic understanding of carcinogenesis. Although retinoids have established activity in this model, a substantial percentage of our OPL patients progress to cancer, especially after treatment is stopped. On the basis of our 10-year OPL study, we have developed the first comprehensive tool for assessing cancer risk of OPL patients. This cancer risk assessment tool incorporates medical/demographic variables, epidemiological factors, and cellular and molecular biomarkers. Between 1988 and 1991, 70 advanced OPL patients were enrolled in a chemoprevention trial of induction with high dose isotretinoin (1.5 mg/kg/day for 3 months) followed by 9 months of maintenance treatment with either low dose isotretinoin (0.5 mg/kg/day) or beta-carotene (30 mg/d; total treatment duration, 1 year). We assessed the relationship between cancer risk factors and time to cancer development by means of exploratory data analysis, logrank test, Cox proportional hazard model, and recursive partitioning. With a median follow-up of 7 years, 22 of our 70 patients (31.4%) developed cancers in the upper aerodigestive tract following treatment. The overall cancer incidence was 5.7% per year. The most predictive factors of cancer risk are OPL histology, cancer history, and three of the five biomarkers we assessed (chromosomal polysomy, p53 protein expression, and loss of heterozygosity at chromosome 3p or 9p). In the multivariable Cox model, histology (P = 0.0003) and the combined biomarker score of chromosomal polysomy, p53, and loss of heterozygosity (P = 0.0008) are the strongest predictors for cancer development. Retinoic acid receptor beta and micronuclei were not associated with increased cancer risk. We have demonstrated a successful strategy of comprehensive cancer risk assessment in OPL patients. Combining conventional medical/demographic variables and a panel of three biomarkers can identify high risk patients in our sample. This result will need to be validated by future studies. With the identification of high risk individuals, more efficient chemoprevention trials and molecular targeting studies can be designed.